These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31789892)

  • 21. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.
    Zamek-Gliszczynski MJ; Zhang X; Mudunuru J; Du Y; Chen JL; Taskar KS; Huang J; Huang Y; Romach EH
    Drug Metab Dispos; 2019 Aug; 47(8):890-898. PubMed ID: 31167838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
    Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
    Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weighing considerations with newer antiretrovirals.
    Venter WDF; Hill A
    Lancet HIV; 2020 Jun; 7(6):e374-e375. PubMed ID: 32504568
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
    Fulco PP; Leibrand Kaczmar CR; Gomes D; Smith T
    J Clin Pharm Ther; 2020 Apr; 45(2):394-396. PubMed ID: 31765502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptotic colitis owing to dolutegravir.
    Martín-Vicente N; Rodríguez-Lago I; Barredo Santamaría I; Cabriada JL
    Gastroenterol Hepatol; 2020 Dec; 43(10):638-639. PubMed ID: 32680730
    [No Abstract]   [Full Text] [Related]  

  • 29. Do Integrase Inhibitors Cause Weight Gain?
    Wood BR
    Clin Infect Dis; 2020 Mar; 70(7):1275-1277. PubMed ID: 31100105
    [No Abstract]   [Full Text] [Related]  

  • 30. Author reply to Copp et al. (2022) correspondence.
    Posobiec L
    Birth Defects Res; 2022 Jul; 114(12):682. PubMed ID: 35694997
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
    Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
    Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

  • 34. Weight gain and aging in people with HIV.
    Taramasso L; Stapleton JT; Siedner MJ
    AIDS; 2021 May; 35(6):987-989. PubMed ID: 33821824
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What will it take to refute the possible safety signal for dolutegravir and neural tube defects?
    Zash RM
    BJOG; 2019 Oct; 126(11):1346. PubMed ID: 31283097
    [No Abstract]   [Full Text] [Related]  

  • 37. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of the Key Dolutegravir Intermediate via MgBr
    Kong J; Xia H; He R; Chen H; Yu Y
    Molecules; 2021 May; 26(10):. PubMed ID: 34064812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
    Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
    Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.